473 related articles for article (PubMed ID: 4204708)
1. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
[No Abstract] [Full Text] [Related]
2. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
Cabana BE
Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
[TBL] [Abstract][Full Text] [Related]
3. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
Schnieders B
Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of drugs (first of two parts).
Koch-Weser J
N Engl J Med; 1974 Aug; 291(5):233-7. PubMed ID: 4600408
[No Abstract] [Full Text] [Related]
5. Guidelines for evaluation of drugs for use in man. Report of a WHO scientific group.
World Health Organ Tech Rep Ser; 1975; (563):1-59. PubMed ID: 803745
[No Abstract] [Full Text] [Related]
6. Bioavailability of drugs (second of two parts).
Koch-Weser J
N Engl J Med; 1974 Sep; 291(10):503-6. PubMed ID: 4604153
[No Abstract] [Full Text] [Related]
7. [Pharmacology and practical therapy. Principles for the selection of application form of a drug and its mode of origin].
Levy G; Barr WH
Internist (Berl); 1973 Dec; 14(12):661-7. PubMed ID: 4593013
[No Abstract] [Full Text] [Related]
8. Bioavailability, clinical effectiveness, and the public interest.
Levy G
Pharmacology; 1972; 8(1):33-43. PubMed ID: 4644654
[No Abstract] [Full Text] [Related]
9. Application of metabolic data to the evaluation of drugs. A report prepared by the committee on problems of drug safety of the drug research board, National Academy of Sciences-National Research Council.
Clin Pharmacol Ther; 1969; 10(5):607-34. PubMed ID: 4980111
[No Abstract] [Full Text] [Related]
10. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-fourth report.
World Health Organ Tech Rep Ser; 1972; 487():1-86. PubMed ID: 4623961
[No Abstract] [Full Text] [Related]
11. The significance of properly designed pre-clinical studies in the clinical evaluation of new drugs.
Garrett ER
Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):6-20. PubMed ID: 4924331
[No Abstract] [Full Text] [Related]
12. [Possibilities and propositions of teaching biopharmacy in education of pharmacists].
Kedvessy G
Pharmazie; 1971 Nov; 26(11):655-6. PubMed ID: 5154314
[No Abstract] [Full Text] [Related]
13. Biopharmaceutics and applied pharmacy.
Krówczyński L
Pharmazie; 1971 Nov; 26(11):659. PubMed ID: 5154316
[No Abstract] [Full Text] [Related]
14. Some factors affecting bioavailability of drug products.
Lach JL
J Iowa Med Soc; 1972 Aug; 62(8):441-2 passim. PubMed ID: 5044776
[No Abstract] [Full Text] [Related]
15. Evaluation and testing of drugs for mutagenicity: principles and problems. Report of a WHO Scientific Group.
World Health Organ Tech Rep Ser; 1971; 482():1-18. PubMed ID: 5003605
[No Abstract] [Full Text] [Related]
16. Bioavailability of peroral dosage forms.
Ritschel WA
Boll Chim Farm; 1973 Mar; 112(3):137-62. PubMed ID: 4198518
[No Abstract] [Full Text] [Related]
17. The use of essential drugs. Third report of the WHO Expert Committee.
World Health Organ Tech Rep Ser; 1988; 770():1-63. PubMed ID: 3140500
[No Abstract] [Full Text] [Related]
18. The use of essential drugs. Report of a WHO expert committee.
World Health Organ Tech Rep Ser; 1983; 685():1-46. PubMed ID: 6408810
[No Abstract] [Full Text] [Related]
19. [Biopharmacy and pharmacokinetics].
Janků I
Pharmazie; 1971 Nov; 26(11):660. PubMed ID: 5154317
[No Abstract] [Full Text] [Related]
20. [Biologic availability of drugs in humans and animals].
Wichliński L
Pol Tyg Lek; 1975 Dec; 30(50):2111-2. PubMed ID: 1197106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
